Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD - HCPLive

A research team led by the Molecular and Cellular Neurobiotechnology group at the Institute for Bioengineering of Catalonia (IBEC), in collaboration with Míriam Royo's laboratory at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), the University of Barcelona (UB) and the Institute for Research in Biomedicine (IRB Barcelona), has identified a synthetic peptide that reduces the production of amyloid beta (Aβ).

The same patient, identified and re-consented for the third or fourth time across separate studies, is not an edge case. It is how clinical research is currently structured, and the inefficiency is measurable: every redundant records request, re-registration, and repeat consent conversation adds cost to the sponsor and time to a patient already managing a demanding diagnosis. The case building around patient-owned health data argues that the architecture itself is the problem, not the execution. The traditional model treats each protocol as a discrete relationship. A trial opens, participants are found, data flows inward, and the relationship ends. But sponsors rarely stop needing evidence from the same populations once a study closes. Observational work, real-world outcomes, label extensions, and post-market commitments all draw on the same patient groups, rebuilt from scratch each time. What the patient-owned model proposes instead is a single consented relationship that persists across those activities, turning what was an episodic research interaction into ongoing infrastructure.